Trial Profile
REGULATory T-Cell Inhibition With Basiliximab (Simulect) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary) ; Umitrelimorgene autodencel (Primary) ; Autolymphocyte therapy; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms REGULATe
- 22 Aug 2019 Status changed from active, no longer recruiting to completed.
- 05 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 05 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.